ESPE Abstracts

Background: GLP-1 agonists have a special place in the treatment of type 2 diabetes mellitus (T2DM). Dulaglutide is GLP-1agonist with important advantages, it doesn’t cause hypoglycemia, reduces weight and decreases HbA1c with sufficient level. GLP-1 agonists are also involved in the treatment of obesity.

Objectives: The purpose of this study was to present the efficacy of Dulaglutide (GLP-1) in obesity with and without T2DM.

Methods and Results: 126 patients were enrolled in the study. 65 of them had both T2DM and obesity. Middle age of the patients of this group was 38.6 years (28.6-61.4), sexual distribution-31 male and 34 female. The duration of T2DM was up to 5 years. In another group 51 patients only with obesity were involved, whose middle age was 36.7years (28.1-54.3), sexual distribution-35 female and 16 male. The study duration was 8 weeks, during which patients of both groups received metformin 2000 mg every day and Dulaglutide 1.5 mg once a week. In the T2DM and obesity group BMI was 34.3 ±2.3 kg/m2, HbA1c-8.1% (7.0-8.9) and only in the group of patients with obesity BMI 36.0 ±2.7 kg/m2, HbA1c-5.2 %(4.3-5.7). As a result of 8 weeks combined treatment in patients with obesity and T2DM reduced BMI with 3.3 kg/m2 or 9.6% (P<0.001). was recorded Weight loss was more evident in other group, about 4.4 kg/m2 or 11.1 %. In the first group decreased HbA1c about 2.6% (P<0.001)was also recorded.

Conclusions: Combination of GLP-1 and metformin is very effective from the point of view of diabetes compensation and weight loss, which reduces the probability of cardiovascular accidents, at the same time, weight loss improves the quality of life.

References: Jamy Ard, Angela Fitch, Sharon Fruh, Lawrence Herman Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists Epub 2021 May 11. Adv Ther 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0.